secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001104659-24-007811
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute appoints Daron Evans as CFO; receives UK Innovation Passport for RZ358
-------------------------------------------------------------------------------

- Daron Evans appointed CFO, effective Jan 23, 2024; base salary $275,000, target bonus 50%.
- Received inducement grant of 275,000 stock options at $1.02 (closing price), vesting over 4 years.
- UK MHRA awarded Innovation Passport to RZ358 for congenital hyperinsulinism treatment.
- Innovation Passport is entry to ILAP, aims to accelerate time to market and patient access.
- Phase 3 study for RZ358 initiated; Phase 2 RZ402 data expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924007811/0001104659-24-007811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924007811/tm244315d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-007811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer